FYE March 2026 Full-Year Financial Results

…for patient comfort.

Full-Year FY2026 Results

Date of Release: May 7, 2026

Earnings Call: May 8, 2026

AI CFO Presentation Available Here!

Release:10:00 AM, May. 8, 2026 (JST)

TSE Prime Market Ticker 7575

Unauthorized copying prohibited.

Copyright © 2026 Japan Lifeline Co., Ltd. All rights reserved.

1. FY2026 Results

2. FY2027 Guidance

   AI CFO Presentation

   Release: 10:00 AM, May. 8, 2026 (JST)

   
   
   

3. Medium-Term Strategy Update

4. Q&A Session

Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)

A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/

[Note] The fiscal year (FY) ends on March 31 of each year. 'FY20XX' refers to the fiscal year ending March 31, 20XX unless otherwise stated. 2

1. FY2026 Results

2. FY2027 Guidance

3. Medium-Term Strategy Update

4. Q&A Session

Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)

A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/

[Note] The fiscal year (FY) ends on March 31 of each year. 'FY20XX' refers to the fiscal year ending March 31, 20XX unless otherwise stated. 3

Highlights

External

Factors

Net sales, operating profit, and net profit all reached record-highs

(+) AF procedure volume nearly +10% YoY

(ー) PFA*2 impacts on select products

Internal Factors

(+) Strong sales of core products*3

(+) Continued double-digit growth in New TAs*4

(ー) Increase in personnel and R&D expenses

(ー) Inventory write-down & HQ relocation costs

4

*1 Profit attributable to owners of parent *2 Pulsed Field Ablation; becoming widespread as a new treatment for arrhythmia *3 Four highly competitive products of special focus: (1) Intracardiac

defibrillation catheter [EP/ABL], (2) Femoral vein hemostatic device [EP/ABL], (3) S-ICD [CRM], (4) Frozen Elephant Trunk [CV] *4 Neurovascular and Gastrointestinal

• Growth in sales & profit; net sales, OP, and NP reached record highs

  (¥mn except for per share amount)

  Net sales Gross profit

  FY2025

  56,610

  	%	60.4%	59.4%		(100bps) (ー) Product mix deteriorated
  SG&A		21,864	22,567	+703	+3.2% (ー) Personnel and R&D expenses increased

  34,191

  FY2026

  ATH

Change

Amount %

Comments

(+) Sales volume increased with more cases (+) New therapeutic areas expanded

(+) Sales volume increased with more cases (ー) Reimbursement revision (2-mon impact)

*1 Profit attributable to owners of parent *2 Cholangioscopy system [GI] *3 Endoscopic laser ablation catheter "HeartLight X3"[EP/Ablation] *4 Recorded 351 million yen in deferred tax assets, as it 5

became highly probable that temporary differences related to valuation losses on investment securities would reverse within a foreseeable period.

• Growth in core products & new TAs offset PFA impacts and higher SG&A, securing profit growth

  • Personnel

  (462)

  • R&D (251)

  • Sales-related (212)

  New TAs

  • Neuro

  • Gastro

  +349

  +296

  • PFA impact (1,094)

  (Eso catheter & others)

  Core Products*1

  • Defibrillation

    catheter(BeeAT) +888

  • Hemostatic device +685

  • FET *² +128

  • S-ICD +6

    +1,708

    +646

    Other products

    Increase in SG&A expenses

    (Excl. one-off)

    YoY

    + 280

    Up 2.3%

    (¥mn)

    12,326

    New TAs

    (941) (430) +377

    12,606

    Core Products

    (1,080)

    One-off factors (Positive)

    • Bad Debt Related *⁴ +387

    • Misc. Income *⁵ (10)

  • Selling price decline (185)

  • Reimbursement revision

    (100)

  • Sales transfer (a certain

  product in GI) (138)

Sales volume Unit price*3

FY2025

Operating Profit

Sales/COGS-related factors

+983

SG&A-related factors

(703)

FY2026

Operating Profit

*1 Strategically focused products *2 Frozen Elephant Trunk *3 Main factors include changes in selling/cost prices, and impact from product disposal/valuation loss *4 Recorded ¥199mn provision for doubtful accounts for one 6

client in FY2025. Reversed ¥199mn of this provision in FY2026 due to partial debt recovery. *5 Misc. income related to inventory transfer following termination of Baylis product sales agreement occurred in Q1 FY2025

• Net sales and operating profit slightly missed guidance; net profit landed on plan

  aided by tax credits

  (¥mn)

  59,300

  Net sales

  
  
  

  Vs. Full-year

  Guidance

  99.8%

  59,187

  59,300

  (¥mn)

  12,900

  Operating profit

  12,900

  (¥mn)

  Vs. Full-year

  Guidance

  97.7%

  12,606

  9,824

  6,620

  6,300

  3,272

  3M

  6M

  9M

  12M

  FY2026

  
  
  

  Net income

  9,350

  Vs. Full-year

  Guidance

  100.4%

  9,350

  6,821

  4,774

  4,500

  2,302

  3M

  6M

  9M

  12M

  FY2026

  
  
  

  9,350

  44,475

  44,405

  9,675

  7,013

  29,650

  29,285

  29,300

  6,450

  4,675

  14,825

  14,616

  3,225

  2,338

  0 0

  3M 6M 9M 12M FY2026

  Actual Guidance
  
  Actual Guidance
  
  

  0

  Actual Guidance 7
  
  

  Existing Businesses Composition: 92%*1

  CRM (Cardiac Rhythm Management)

  22%

  EP/Ablation

  49%

  Cardiovascular

  21%

  • Implantable electric devices to treat arrhythmias

    Stable

  • Medical tubes used in arrhythmia procedures

    [Core Product]

    • Vascular grafts used in aortic surgeries

      Core

      Business

      [Core Product] S-ICD

      Intracardiac Defibrillation Catheter

      [Core Product] Hemostatic Device

      Business

      [Core Product] Frozen Elephant Trunk

      New Therapeutic Areas Composition: 8%*1

      Neurovascular

      • Medical devices used to treat neurovascular diseases

  5%

  High

  Gastrointestinal 3%

  • Medical devices used to treat digestive diseases

    *1 Composition rates are actual results for FY2026

    Aspiration Catheter

    Embolic Coil

    Growth Business

    Bile-Duct Tube Stent 8

    
    
    

    Sales

    
    
    

    • Revenue tied to procedure volume

      Number of procedures

      Our market share

      Official Prices

      Wholesale price rate

      Volume

      Unit Price

      
      
      
      
      
      
      

      --> National health insurance reimbursement prices (NHI)

      
      
      

      Most of our products are single-use medical devices used in surgeries 9

      • Achieved +4.6% YoY sales growth driven by expansion in existing & new TAs

        YoY

        (¥mn)

        FY2025

        Net Sales

        Discontinued operations

        (Coronary

        +2,577

        +819

        56,610

        Cardiac Rhythm Management

        +1,264

        +451

        Cardiovascular Neurovascular

        +316

        Gastrointestinal

        Intervention)

        (63)

        59,187

        (210) EP/Ablation

        Existing businesses

        +1,504

        New therapeutic areas

        +1,135

        Up 4.6%

        FY2026

        Net Sales 10

        
        
        

        FY2026 Cardiac Rhythm Management

        New TAs

        Existing Businesses

        
        
        Lead management launch offsets pacemaker decline
        
        
        
        

        Net Sales Sales Highlights

        (¥mn)

        • T-ICD

        • CRT-D

        • AED

and others

13,267

YoY

(1.6%)

(14.2%)

13,057

Lead Extraction

+0.4%

S-ICD

FY2025 FY2026

*1 ICD implantation before the onset of lethal arrhythmia to prevent sudden cardiac death

EMBLEM S-ICD

(Boston Scientific)

Lead extraction device

TightRail

(Philips) 11

Net Sales Sales Highlights

(¥mn)

• Ablation catheter

• Steerable sheath

• Export sales and others

Radiofrequency Transseptal Wire XEROstar

(Proprietary product)

27,845

YoY

(3.4%)

(47.6%)

+61.7%

+7.6%

29,109

Hemostatic

Device

Defibrillation Catheter

Eso Catheter

(+) AF procedure volume: nearly +10% YoY

(+) Defibrillation catheter: +7.6% YoY

• Volume +8.6%; Est. 95% market share (Mar. 26)

  Core Product

(+) Hemostasis device: +61.7% YoY

• Number of adopting mid-small facilities increased; contribution from additionally introduced large size began

  (ー) PFA*2 impact

• PFA penetration: 65% of all AF cases (slight increase from Q3)

• Sales of Eso catheter and EP catheter declined However, the impact largely ran its course in Q3

  (+) Launched proprietary transseptal wire

• Received generally high evaluations in initial clinical use

FY2025 FY2026

*1 PFA = Pulsed Field Ablation, a new catheter ablation treatment method promoted by three foreign competitors *2 Electrophysiology catheters excluding intracardiac defibrillation catheter 12

and esophageal temperature monitoring catheter

Net Sales Sales Highlights

(¥mn)

• ASD closure devices

• TAVI guidewire

• Delivery catheter system for Heartseed and others

Frozen Elephant Trunk Integrated graft model Frozenix 4 Branched

(Proprietary product)

12,206

YoY

(1.7%)

+4.6%

+3.9%

12,657

Frozen Elephant Trunk

Core

Others

• Domestic market volume +3.1%; maintained 90% market share (est. Mar. 26)

  (+) Vascular graft: +4.6% YoY

• Competitor product line exits driving share gains

  (ー) EVAR*1: (1.7%) YoY

• Impacted by intensified competition

  (+) Others

• Sensor-equipped TAVI*2 guidewire (from Q2)

• Collab with Heartseed, selling delivery catheter system (Q2)

  FY2025 FY2026

  *1 Endovascular Aortic Repair; treated with abdominal stent grafts *2 TAVI=Transcatheter Aortic Valve Implantation 13

  Strong aspiration catheters; new models drive coil growth
  
  
  
  

  Net Sales Sales Highlights

  (¥mn)

  • Microcatheter and others

    1,842

    YoY

    FY2025

    2.0x

    Others

FY2026

+19.6%

2,661

• Highly evaluated product performance driving expansion in adopting facilities; Est. 20% market share

  (+) Embolic coils: +19.6% YoY

• Increased market awareness; expanded range of cases

• Progress in opening new sales channels (e.g., Radiology dept.)

1.7x

Embolic Coil

MEGAnir HELICAL

(New radiology-focused model, Wallaby Medical)

Aspiration Catheter

Esperance 3+

(New distal vessels-focused model, Wallaby Medical)

Stent Retriever

pRESET

(phenox, a company of

Wallaby Medical Group 14

Net Sales Sales Highlights

(¥mn)

1,345

YoY*1

(34.0%)

+10.0%

2.2x

1,661

• New model launched in Q1 received favorable reception; prioritized existing customers due to inventory constraints

  (+) ERCP guidewire: 2.2x YoY (+) GI stents: +10.0% YoY

• Recovering from previous year's voluntary recall impact

  (ー) Liver cancer ablation needle: (34.0%) YoY

• Selling price impacted by shift to partner-led distribution

model

+49.3%

FY2025 FY2026

Bile-Duct Tube Stent

REGULUS

(Proprietary product)

Straight model Pigtail model (New)

*1 Excluding discontinued PCI (percutaneous coronary intervention) business. Reported Gastrointestinal segment net sales including PCI: FY2025 ¥1,448mn vs FY2026 ¥1,701mn (+17.4% YoY) 15

1. FY2026 Results

2. FY2027 Guidance

3. Medium-Term Strategy Update

4. Q&A Session

Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)

A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/

[Note] The fiscal year (FY) ends on March 31 of each year. 'FY20XX' refers to the fiscal year ending March 31, 20XX unless otherwise stated. 16

Full-Year Earnings Guidance

External Factors

(+) AF procedure volume +9% YoY

(ー) Reimbursement price decline (Jun. 2026) (ー) Higher manufacturing costs and SG&A

due to inflation

Internal

Factors

(+) Solid core product*2 sales

(ー) Acceleration of growth investments (ー) HQ relocation costs

17

*1 Profit attributable to owners of parent *2 Five highly competitive products of special focus: (1) Intracardiac defibrillation catheter [EP/Ablation], (2) Femoral vein hemostatic device [EP/Ablation], (3) Transseptal wire "XEROstar" [EP/Ablation] (Newly added from FY2027), (4) S-ICD [Rhythm Devices], (5) Frozen Elephant Trunk [Cardiovascular]

• Expect record sales; lower profit due to deliberate future investments

  (¥mn except for per share amount)	FY2026	FY2027 Est.	Change		Comments
  			Amount	%
  Net sales	59,187	ATH 63,200	+4,012	+6.8%	(+) Sales volume increased with more cases and new products (ー) Reimbursement price decline (Jun. 26; 10-month impact)
  Gross profit	35,174	36,600	+1,425	+4.1%	(+) Sales support for competitor's RF needle ended (Dec. 2025) -> Shift to proprietary product sales (from Mar. 2026) (ー) Increase in manufacturing costs (raw materials and labor costs)
  %	59.4%	57.9%	(150bps)
  SG&A	22,567	25,900	+3,332	+14.8%	(ー) Acceleration of growth investments including R&D expenses (ー) Increase in personnel expenses (ー) Higher SG&A expenses due to inflationary pressures (ー) Non-recurring expenses incl. one-time HQ relocation costs
  Operating profit	12,606	10,700	(1,906)	(15.1%)
  %	21.3%	16.9%	(440bps)
  Net income*1	9,350	8,000	(1,350)	(14.4%)	(+) Sale of investment securities (Extraordinary income) (+) Decrease in fixed asset disposal losses (Extraordinary loss)
  %	15.8%	12.7%	(310bps)
  Proprietary sales mix	56.0%	57.9%	+190bps		Procured product sales: +2% YoY Proprietary product sales: +10% YoY
  International sales mix	2.5%	2.7%	+20bps
  Basic EPS (¥)	131.43	114.02	(17.41)	(13.3%)

  *1 Profit attributable to owners of parent

  
  
  

  • Solid sales, but profit down on strategic investments, one-off costs, and inflation

    • Core Products*¹ +2,520

      Defibrillation catheter +1,200

      RF Wire +880

      Others +440

    • New TAs +420

    • Other products (490)

      Sales support for RF needle (440)

      +2,450

      Unit price Impact

      and other factors *2

      (1,025)

      Increase in SG&A

      expenses

      (Excl. growth investments and one-off factors)

    • Personnel (900)

    • Depreciation (300)

    • IT-related (180)

      Increase in growth

      YoY

      (1,906)

      (¥mn)

      12,606

      Sales volume impact

      • Selling price decline (320) (Reimbursement price cut)

        (1,217)

        investments

        (1,300)

        One-off factors

        (814)

        Down 15.1%

        10,700

        • Increase in mfg costs (610)

          (Raw materials and labor costs)

        • R&D investment (1,040)

        • Malaysia factory (260) (establishing OEM mfg line)

        • HQ relocation-related

          (596)

        • Bad debt related*³ (218)

    FY2026

    Operating Profit

    Sales/COGS-related factors

    +1,425

    SG&A-related factors

    (3,332)

    FY2027

    Operating Profit Est.

    19

    *1 Five highly competitive products of special focus: (1) Intracardiac defibrillation catheter [EP/Ablation], (2) Femoral vein hemostatic device [EP/Ablation], (3) RF transseptal wire [EP/Ablation] (newly added this time), (4) S-ICD [Rhythm Devices], (5) Frozen Elephant Trunk [Cardiovascular] *2 Mainly comprised of changes in unit selling prices and unit manufacturing costs. Includes impact from product disposal and inventory valuation losses and other factors. *3 FY2026: Recorded reversal of allowance for doubtful accounts related to a specific customer

    
    
    

    • Price revision impact limited: approx. ¥400mn net sales reduction, significantly lighter than the previous cycle

*1 Assumes all other variables remain constant, isolating the impact of price revisions. *2 Calculated as (net sales after revision / net sales before revision) -1*100 20